Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mortality factor 4-like protein 2 (MORF4L2), also known as MORF2, is a member of the MRG family of proteins and a key component of the NuA4 histone acetyltransferase complex (UniProt Q15014). It plays a critical role in chromatin remodeling and transcriptional regulation by facilitating the acetylation of histones H4 and H2A (PubMed: 11433365). Beyond transcription, MORF4L2 is involved in DNA damage repair, particularly through its interaction with the BRCA1-BARD1 complex in homologous recombination (PubMed: 21572988). In a clinical context, MORF4L2 is often overexpressed in various malignancies, including breast and cervical cancers, where it promotes cell proliferation and survival (PubMed: 28651084). While it is an area of active research for its role in oncogenesis and senescence, there are currently no approved therapeutic agents specifically targeting MORF4L2 (PubMed: 31235912).
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mortality factor 4-like protein 2 (MORF4L2) (MORF4L2).